Business Context and Reporting Period
Company: Phio Pharmaceuticals Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: May 7, 2025
Reporting Period: Event-based report for May 7, 2025.
Phio Pharmaceuticals Corp. is a Delaware corporation with its principal executive offices in Marlborough, Massachusetts. The company's common stock trades on The Nasdaq Capital Market under the symbol "PHIO".
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material event reported is the announcement of clinical trial results:
- Event: Announcement of results from the third cohort of an ongoing Phase 1b dose escalation clinical trial.
- Study Identifier: NCT 06014086.
- Subject: Evaluation of the safety and tolerability of the neoadjuvant use of INTASYL PH-762.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release (Exhibit 99.1) detailing the clinical trial results. No specific forward-looking guidance, financial outlook, or management commentary is included within the body of this 8-K text.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the inherent uncertainties associated with clinical trial outcomes referenced in the event description.
Investor Verification Checklist
- Review the full text of the press release attached as Exhibit 99.1 for specific safety and tolerability data regarding INTASYL PH-762.
- Verify the clinical trial status and future cohort plans via the ClinicalTrials.gov identifier NCT 06014086.
- Check subsequent filings for any updates on the trial's progression or potential impact on the company's development timeline.